SUMMARY
Infectious diseases (ID) represent a significant proportion of morbidity and mortality across the world. Host genetic variation is likely to contribute to ID risk and downstream clinical outcomes, but there is a need for a genetics-anchored framework to decipher molecular mechanisms of disease risk, infer causal effect on potential complications, and identify instruments for drug target discovery. Here we perform transcriptome-wide association studies (TWAS) of 35 clinical ID traits in a cohort of 23,294 individuals, identifying 70 gene-level associations with 26 ID traits. Replication in two large-scale biobanks provides additional support for the identified associations. A phenome-scale scan of the 70 gene-level associations across hematologic, respiratory, cardiovascular, and neurologic traits proposes a molecular basis for known complications of the ID traits. Using Mendelian Randomization, we then provide causal support for the effect of the ID traits on adverse outcomes. The rich resource of genetic information linked to serologic tests and pathogen cultures from bronchoalveolar lavage, sputum, sinus/nasopharyngeal, tracheal, and blood samples (up to 7,699 positive pathogen cultures across 92 unique genera) and a large catalog of genome-wide associations of microbiome variation generated from phylogenetic analysis of 16S rRNA gene sequences are developed here into a platform to interrogate the genetic basis of compartment-specific infection and colonization. To accelerate insights into cellular mechanisms, we develop a TWAS repository of gene-level associations in a broad collection of human tissues with 79 pathogen-exposure induced cellular phenotypes as a discovery and replication platform. Cellular phenotypes of infection by 8 pathogens included pathogen invasion, intercellular spread, cytokine production, and pyroptosis. These rich datasets will facilitate mechanistic insights into the role of host genetic variation on ID risk and pathophysiology, with important implications for our molecular understanding of potentially severe phenotypic outcomes.
HIGHLIGHTS
Atlas of genome-wide association studies (GWAS) and transcriptome-wide association studies (TWAS) results for 35 clinical infectious disease (ID) phenotypes, with genome-wide and transcriptome-wide significant results for 13 and 26 clinical ID traits, respectively
Phenome-scale scan of ID-associated genes across 197 hematologic, respiratory, cardiovascular, and neurologic traits, facilitating identification of genes associated with known complications of the ID traits
Mendelian Randomization analysis, leveraging naturally occurring DNA sequence variation to perform “randomized controlled trials” to test the causal effect of ID traits on potential outcomes and complications
A genomic resource of TWAS associations for 79 pathogen-induced cellular traits from High-throughput Human in vitrO Susceptibility Testing (Hi-HOST) across 44 tissues as a discovery and replication platform to enable in silico cellular microbiology and functional genomic experiments
Competing Interest Statement
E.R.G. receives an honorarium from the journal Circulation Research of the American Heart Association, as a member of the Editorial Board. He performed consulting on pharmacogenetic analysis with the City of Hope / Beckman Research Institute.
Funding Statement
A.T.H. is supported by the National Institutes of Health (F30HL143826) and Vanderbilt University Medical Scientist Training Program (T32GM007347). E.R.G. is supported by the National Human Genome Research Institute of the National Institutes of Health under Award Number R35HG010718. E.R.G and S.S.Z. are funded by the National Heart, Lung, & Blood Institute of the National Institutes of Health under Award Number R01HL133559. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. E.R.G. has also significantly benefitted from a Fellowship at Clare Hall, University of Cambridge (UK) and is grateful to the President and Fellows of the college for a stimulating intellectual home. Genomic data are also supported by individual investigator-led projects including U01-HG004798, R01-NS032830, RC2-GM092618, P50-GM115305, U01-HG006378, U19-HL065962, and R01-HD074711. Additional funding sources for BioVU are listed at https://victr.vanderbilt.edu/pub/biovu/. L.B. is supported by R01-LM010685. S.J.S. is supported R01-EB1019804, R01-AI145057, R01-EB014641, R01-HD085853, and DP1-HD086071. D.C.K. is supported by R01-AI118903, R21-AI144586, and R21-AI146520. D.C.K. and L.W. are supported by R21-AI133305.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Vanderbilt University Medical Center IRB
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All results and code are available at the links below.
